Navigation Links
Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
Date:8/11/2008

LOS ANGELES, California and GUANGZHOU, China, August 12 /PRNewswire-FirstCall/ --

- Major Threat Treatable With StatC(TM); FDA-Approved Drugs to Begin Testing in U.S. Animal Models

An internationally renowned avian influenza expert today hailed "encouraging and exciting" results from experiments conducted by his research team. This study demonstrated impressive efficacy of a novel statin/caffeine combination, StatC(TM) in the treatment and prevention of H5N1, H1N1 and H3N2 in a mouse model.

To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/canopusbiopharma/34441/

Dr. Jiahai Lu, from the School of Public Health, Sun Yat-sen University in Guangzhou, China, has published extensively in the field of avian influenza, and has been researching the breakthrough compound StatC(TM) for the past two years on behalf of Canopus Biopharma (OTCPK:CBIA), a US corporation who discovered and patented the potential of this antiviral candidate.

"The global distribution of the highly pathogenic H5N1 avian influenza has caused the World Health Organization to show its profound concern regarding the possibility of the virus spreading from human to human in the future," stated Dr. Lu. "Furthermore, the development of resistance to two approved anti-influenza drugs, oseltamivir (Tamiflu(R)) and zanamivir (Relenza(R)), as well as the lack of adequate vaccines has increased the need of developing new antiviral drugs."

"Consequently, I am delighted to be involved in the preclinical research stage of this innovative antiviral candidate, and look forward to continuing our successful collaboration with Canopus Biopharma in this area."

Dr. Lu and his colleagues have conducted extensive animal studies with StatC(TM) against three influenza strains, H5N1 (avian influenza, bird flu), H1N1 (Spanish influenza) and H3N2 (Hong Kong influe
'/>"/>

SOURCE Canopus Biopharma INC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
4. ARCA biopharma Appoints James Carr as Vice President of Marketing
5. TriCipher is First to Transfer Smart Card Level Security to Federally Approved SAFE-BioPharma(TM) Roaming Credentials
6. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
7. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
8. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
9. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
10. Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry
11. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a leader in ... is to open in Manhattan, Kansas in early October, 2015. The location of ... research and development through collaboration with researchers from Kansas State University’s College of ...
(Date:8/26/2015)... Maryland Heights, MO (PRWEB) , ... August 26, ... ... is announcing it is increasing its investment in the development and manufacture of ... increase demand. The company’s scientific team's extensive expertise with protein chemistry has ...
(Date:8/26/2015)... -- Intrexon Corporation (NYSE: XON ), a leader ... previously announced public offering of common stock, including the ... to purchase an additional 731,707 shares of common stock ...  The exercise of the underwriters, option brought the total ... to 5,609,756 shares and increased the total gross proceeds ...
(Date:8/26/2015)... England , August 26, 2015 ... Ltd against Europlasma NV relating to P2i United ... have resolved their dispute in the United States ... liability on the part of either party. As a result ... Central District of California dismissed the ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2
... Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical company ... diseases, today,announced that it has received approval from ... of its common stock from,the Nasdaq Global Market ... effective as of the opening of the market ...
... II DATA FOR LEAD DRUG CANDIDATE ARIKACE(TM) DRIVES,CONTINUED ... Transave, Inc., a,biopharmaceutical company focused on developing ... lung diseases,today announced that it has secured a ... Horizon Funding Company LLC, an affiliate of Horizon,Technology ...
... children,s hospitals in nation selected as Top Hospital ... by the Leapfrog Group, ... of only seven children,s hospitals in the nation to have been,selected as ... more than 1,220 participating hospitals., Children,s Hospital,s recognition was based on ...
Cached Biology Technology:EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market 2EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market 3Transave, Inc. Secures $12.5 Million in New Financing 2Transave, Inc. Secures $12.5 Million in New Financing 3Transave, Inc. Secures $12.5 Million in New Financing 4Transave, Inc. Secures $12.5 Million in New Financing 5Children's Hospital of Pittsburgh of UPMC Receives Prestigious Recognition for Patient Safety Efforts in National Survey 2Children's Hospital of Pittsburgh of UPMC Receives Prestigious Recognition for Patient Safety Efforts in National Survey 3
(Date:8/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... Smart Card Alliance and the EMV Migration Forum.  ... Smart Card Alliance Latin America (SCALA) Chapter provides NXT-ID, ... thought leaders promoting adoption of smart card technology. ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... Fla. --- When it comes to public access, the tree ... University of Florida researchers shows about 70 percent of published ... unable to get to critical data they may need to ... disease control. Scientists are using the genetic data ...
... FORENSICS Mass grave detection . . . ... may gain closure, and killers may receive appropriate punishment, ... clandestine graves. While investigators can find some graves, perhaps ... of Tennessee,s Forensic Anthropology Center and Oak Ridge National ...
... researchers have shown that they can turn genes on or ... is copied into messenger RNA an advance that could ... The technique could also make it easier to engineer ... detect disease, says Timothy Lu, an assistant professor of electrical ...
Cached Biology News:UF scientists encounter holes in tree of life, push for better data storage 2UF scientists encounter holes in tree of life, push for better data storage 3September 2013 story tips 2September 2013 story tips 3An easier way to control genes 2An easier way to control genes 3
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
... anti-Human Alpha 1 Acid Glycoprotein ... Goats were immunized with ... in Freund's adjuvant. The ... to ensure specificity. For ...
...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... in cell culture supernates and serum.1 Each ... on approximately fifteen 96-well plates, provided that ...
Biology Products: